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Objective: HIV infection and hypertensive disorders of pregnancy are common causes of 
maternal mortality in South Africa. Preeclampsia (PE) is a pregnancy-specific disorder that 
contributes to the majority of maternal deaths caused by hypertension in pregnancy. Reduced 
placentation, endothelial dysfunction of multiple organs and inflammation occur during PE. 
Endothelial cells express the adhesion molecule soluble E-selectin (sE-selectin) in response to 
inflammation. This molecule facilitates the cohesion of leukocytes to endothelial cells.  
In PE, endothelial cell activation and dysfunction cause endothelial cells to secrete the 
glycoprotein thrombospondin-2 (TSP-2). TSP-2 affects cellular functions, plays a regulatory 
role in the extracellular matrix and is an inhibitor of angiogenesis. In PE, an imbalance of 
angiogenic and anti-angiogenic factors result in dysregulation of angiogenesis. 
Considering the high rate of maternal mortality in South Africa due to HIV infection and PE, 
the aim of this study was to investigate the role of sE-selectin and TSP-2 in HIV-associated 
preeclamptic and normotensive pregnancies. 
Method: The study population (n = 72) comprised of normotensive pregnant (n = 36) and 
preeclamptic (n = 36) groups. These groups were further stratified by HIV status (negative vs. 
positive). The Bio-Plex immunoassay technique was used to measure serum concentrations of 
sE-selectin and TSP-2.  
Results: There was a statistical difference observed in gestational age, systolic blood pressure, 
diastolic blood pressure and baby weight across the study groups (p < 0.0001). 
sE-selectin: Based on pregnancy type and HIV status, levels of serum sE-selectin were 
significantly increased in preeclamptic HIV-negative compared to normotensive HIV-negative 
groups (p = 0.0070). 
TSP-2: Regardless of HIV status and based on pregnancy type, TSP-2 levels were 
significantly elevated (p = 0.0429) in preeclamptic compared to normotensive groups. Based 
on HIV status, a significant upregulation (p = 0.0095) of TSP-2 was noted in HIV-positive 
compared to HIV-negative groups. Furthermore, based on pregnancy type and HIV status, 




Conclusion: This study highlights the role of sE-selectin and TSP-2 in preeclamptic women 
compromised by HIV infection and demonstrates the potential biomarker value of sE-selectin 























Inhloso: Ukungenwa yigcinwane leSandulela-ngculazi nezinkinga zempilo ezihlobene nephika 
kubantu abakhulelwe yizona eziyimbangela evamile yokushona kwabesifazane uma bebeletha 
eNingizimu Afrika. I-Preeclampsia (PE) wuhlobo lokugula oluhambisana nokukhulelwa 
okuyilona oluvame ukuba yimbangela yokushona kwababelethayo okudalwa yiphika 
ngesikhathi bekhulelwe. Uma umuntu ene-PE inhliziyo ishaya kancane, amaphaphu akhe 
nezinye izingxenye ezingaphakathi emzimbeni zingasebenzi kahle futhi abe nezinhlungu. 
Ngenxa yezinhlungu, izicubu zamaphaphu azibe zisavuma ukudonsa kalula umoya emaphashini 
okuyisimo semolekhyuli esibizwa nge-sE-selectin. Le molekhyuli isiza ukudluliseleni umoya 
onempilo ezicutshini zamphaphu.  
Uma une-PE, ukusebenza nokungasebenzi kwezicubu zamaphaphu kwenza ukuthi lezi zicubu 
zikhiqize uketshezi olulimaza amaphrotheni i-thrombospondin-2 (TSP-2). I-TSP-2 iphazamisa 
ukusebenza kwezicubu zamaphaphu, idlale indima ekuphazamisekeni kokwakheka kwezicubu 
zamaphaphu futhi icindezela uketshezi olusiza ukuvuselela izicubu zamaphaphu, i-
angiogenesis. Uma une-PE, ukungahambisani ngendlela kokwakhela nokungakheki kwezicubu 
ezintsha emaphashini kuholela ekutheni i-angiogenesis ingabe isasebenza ngendlela.  
Ngokubona amazinga aphezulu okushona kwabantu bebeletha eNingizimu Afrika ngenxa 
yokuhaqwa yiHIV nePE, inhloso yalolu cwaningo bekungukuphenya iqhaza le-sE-selectin ne-
TSP-2 kubantu abakhulelwe abanomfutho wegazi ophezulu nabangenawo umfutho wegazi 
ophezulu. 
Uhlelo Olulandeliwe: Abantu ababambe iqhaza ocwaningweni (n = 72) bahlanganise amaqoqo 
abantu abakhulelwe abangenawo umfutho wegazi ophezulu (n = 36) nabanomfutho wegazi 
ophezulu (n = 36). Lawa maqoqo aphinde ahlukaniswa ngesimo sawo seHIV (abahaqekile 
nabangahaqekile). Kusetshenziswe uhlelo lokubheka isibalo samasosha omzimba lwe-Bio-Plex 
ukuze kubhekwe ubungako be-sE-selectin ne-TSP-2 egazini kwababambe iqhaza.  
Imiphumela: Ngokwemininingwane eqoqiwe ubonakele umehluko uma kuqhathaniswa 
izikhathi zokukhulelwa, umfutho wegazi odalwa yizicubu nalowo odalwa wukusebenza 
kwemithambo kanjalo nesisindo sengane kuwona wonke amaqoqo abeyingxenye yocwaningo 




I-sE-selectin: Ngokubheka uhlobo lokukhulelwa nesimo somuntu seHIV, amazinga oketshezi 
lwe-sE-selectin abephezulu kubantu abanomfutho wegazi ophezulu abangenayo i-HIV uma 
kuqhathaniswa nabantu abangenawo umfutho wegazi ophezulu abangenayo iHIV (p = 0.0070). 
I-TSP-2: Ngaphandle kokubheka isimo somuntu seHIV kodwa ngokubuka isimo sokukhulelwa, 
amazinga e-TSP-2 abephezulu kubantu abanenkinga yomfutho wegazi ophezulu uma 
kuqhathaniswa nabangenayo le nkinga (p = 0.0429). Uma kubhekwa ngokwesimo seHIV, 
kugqame amazinga phezulu impela e-TSP-2 (p = 0.0095) kubantu abaneHIV uma 
kuqhathaniswa nabangenayo i-HIV. Ngaphezu kwalokho, ngokubheka isimo sokukhulelwa 
nesimo seHIV kanye kanye, amazinga e-TSP-2 abephezulu kuwona wonke amaqoqo (p = 
0.0229). 
Isiphetho: Lolu cwaningo lugqamisa iqhaza le-sE-selectin ne-TSP-2 kwabesifazane 
abanenkinga yomfutho wegazi ophezulu abaphinde bahaqwe yiSandulela-ngculazi futhi luveza 
namathuba okuthi kube nendlela eqondile yokuthola ubungako be-sE-selectin ne-TSP-2 



























1.1 Problem statement  
 
Currently in South Africa, there is a high prevalence of maternal deaths due to HIV infection 
and hypertensive disorders in pregnancy. Additionally, it has also been suggested that 
immunosuppressive conditions such as HIV infection  may impact on certain pregnancy 
related complications (Kalumba et al., 2013). Preeclampsia (PE) is a pregnancy specific 
condition that results in endothelial dysfunction, excessive inflammation and dysfunction of 
multiple organs (Gupte and Wagh, 2014). The only effective treatment for PE is expulsion of 
the fetus and placenta via delivery (Pillay et al., 2019). Therefore, research into the duality of 
HIV infection and PE is of immense importance and warrants immediate attention in view of 
the high incidence of maternal deaths in South Africa. 
 
1.2 Human Immunodeficiency Virus (HIV) 
 
HIV is a global health concern with approximately 36.9 million people living with HIV 
infection. Africa is one of the more severely affected regions in the world with an estimated 
25.7 million people being infected (WHO, 2018). In South Africa (SA) the prevalence of HIV 
infection is exceedingly high with 7.97 million people being infected (StatsSA, 2019). 
Furthermore, a serious dilemma to gynaecologists is the fact that in 2019, one-fifth of women 
in the reproductive ages of 15 to 49 years are HIV positive (StatsSA, 2019). In pregnancy,  
HIV infection and hypertensive disorders are the commonest sources of maternal mortality 
and morbidity (Kalumba et al., 2013). 
 
The Human Immunodeficiency Virus (HIV) utilizes a variety of mechanisms to counteract 
and evade the immune system thereby developing into a later stage of disease known as the 
acquired immune deficiency syndrome (AIDS) (Naif, 2013). Immune cells are specifically 
targeted and attacked by HIV within the immune system; thereby impairing their function 
(WHO, 2018). HIV infects and destroys T cells by binding to CD4+ proteins on the cell 
surface (Naif, 2013). The resulting immunodeficiency weakens the immune system and 






1.3.1 Preeclampsia Classification   
Preeclampsia is a hypertensive disorder of pregnancy (Padayachee et al., 2019). The clinical 
stages of this disorder are characterised by new-onset high blood pressure (systolic blood 
pressure ≥140mmHg or diastolic blood pressure ≥90mmHg) and proteinuria (urinary protein 
≥300mg per 24 hours) with such characteristics developing at or after 20 weeks of gestation 
(Brown, 2018). Preeclampsia may be classified by gestational age into two main subtypes 
known as early-onset preeclampsia (EOPE) and late-onset preeclampsia, with early-onset 
preeclampsia being a major cause of maternal and neonatal mortality and morbidity (Gathiram 
and Moodley, 2016).  
1.3.2 Epidemiology  
Preeclampsia is a primary obstetric concern affecting approximately 2-8% of pregnancies 
globally (Salimi et al., 2019). In South Africa, maternal deaths due to hypertension in 
pregnancy are 14.8%, of which 83% are attributed to preeclampsia (NCCEMD, 2018). 
Specifically, the prevalence of preeclampsia in KwaZulu-Natal is 12% (NCCEMD, 2018). 
1.3.3 Aetiology of preeclampsia  
During normal, uncomplicated pregnancies, cytotrophoblasts invade the myometrium of the 
uterus and remodel the spiral arteries (Uzan et al., 2011). Spiral arteries become modified into 
low-resistance, high capacity vessels due to the replacement of the media muscle fibers with a 
fibrinoid type material (Uzan et al., 2011). These flaccid, large-bore vessels then decrease 
resistance to maternal blood flow thus allowing the efficient supply of blood (containing 
oxygen and nutrients) to the fetus, during a process referred to as placentation (Naicker et al., 
2013; Geldenhuys et al., 2018; Armaly et al., 2018). 
The placenta creates an appropriate fetal environment (Salimi et al., 2019) which is crucial for 
growth and development of the fetus within the uterus (Peixoto et al., 2018). During 
pregnancy, the maternal blood supply is utilised by the placenta to enable the growth of the 
fetus by facilitating gaseous exchange, uptake of nutrients and elimination of waste 




Abnormal placentation or impairment of placentation may result in restriction of fetal growth, 
as well as preeclampsia (Peixoto et al., 2018). In preeclampsia, cytotrophoblast invasion is 
decreased and the physiological transformations of spiral arteries are limited to the decidua 
(Naicker et al., 2003). Early-onset preeclampsia in particular, adversely affects both the 
mother and fetus where growth within the uterus is restricted due to a dysfunctional placenta 
(Peixoto et al., 2018). Mechanisms such as spiral artery thrombosis and oxidative stress within 
the placenta are also suggested to be involved in the pathogenesis of preeclampsia (Salimi et 
al., 2019). 
1.3.4 Pathogenesis of preeclampsia  
In EOPE, cytotrophoblasts are unable to invade the lining of the uterus (Geldenhuys et al., 
2018) and the remodelling of myometrial spiral arteries is defective (Gathiram and Moodley, 
2016). Late-onset preeclampsia arises due to placental ischaemia with the resultant increase in 
oxidative stress (Geldenhuys et al., 2018). The ischaemic placenta causes increased 
trophoblast microparticle release, resulting in enhanced pro-inflammatory cytokine induction 
(Raghupathy, 2013). The ‘systemic’ stage of preeclampsia ensues as a result of endothelial 





Figure 1: The stages of progression in preeclampsia. Adapted from (Raghupathy, 2013). 
 
1.3.5 Immune maladaptation 
Paternal, fetal, as well as placental antigens, are foreign to the immune system of the mother 
during pregnancy. Therefore, the regulation of immunological processes prevents fetal 
rejection and also defends the mother against infection (Geldenhuys et al., 2018). The immune 
system of the mother permits fetal exposure to cellular as well as humoral components, thus 
playing an important role during pregnancy (Lokki et al., 2018).  
Usually Th2 polarisation occurs during pregnancy, where the balance between Th1 and Th2 
phenotypes shift toward a Th2 immune response (Rana et al., 2019). However, during 
preeclamptic pregnancies, there is an abnormal shift from the Th2 phenotype to Th1 (Rana et 
al., 2019). Since downregulation of this Th1 immune response does not occur, there is an 
increase in Th1 pro-inflammatory cytokines such as interleukin-18 and tumour necrosis 
factor-alpha (TNF-α) (Geldenhuys et al., 2018).  These cytokines cause trophoblast cells to 




2018; Rana et al., 2019). This pro-inflammatory state affects immune tolerance and leads to 
dysregulation of the immune system in preeclampsia (Geldenhuys et al., 2018).  
The complement system plays a vital role in maintaining immune tolerance;this involves 
activation as well as regulation of proteins which enable differentiation between self and 
foreign cells (Lokki et al., 2018). The complement system is also involved in the elimination 
of pathogens and removal of debris by facilitating phagocytosis however, activation of this 
system can result in destruction of tissues, cell death and inflammation (Figure 2) (Lokki et 








Figure 2: Mechanisms of the immune system in preeclampsia. In preeclampsia, mechanisms of the 
immune system play a role in both the initial and advanced pregnancy stages. Trophoblast cell invasion 
occurs at the bed of the placenta or within spiral arteries of the uterus. The inability of the complement 
system to identify these trophoblasts can result in shallow placentation and also compromise 
remodelling of maternal spiral arteries. During advanced stages of pregnancy, activating the 




and may also lead to placental inflammation being induced. Activation of the immune system can also 
worsen dysfunction of the endothelium, along with a disturbance in the function of coagulation, thus 
causing a shift from Th2- to Th1- cells. Adapted from (Lokki et al., 2018). 
 
1.3.6 Angiogenesis 
During a healthy pregnancy, angiogenesis plays a vital role in meeting the increasing fetal 
metabolic requirements as well as supporting growth and overall health of the fetus (Murthi et 
al., 2014). The process of angiogenesis involves modification of differentiated endothelial 
cells leading to the formation of new blood vessels from pre-existing vessels (Figure 3) 
(Belkacemi et al., 2015). The process of angiogenesis is controlled by pathways in which the 
expression of genes and proteins occur; dysregulation of this expression is suggested to be 
associated with preeclampsia development (Peixoto et al., 2018).   
 
 
Figure 3: The process of angiogenesis. Adapted from (Belkacemi et al., 2015). 
  
1.3.7 Gene expression and preeclampsia  
 
MicroRNAs (miRNAs) are regulatory molecules that have the ability to suppress and 
upregulate gene expression within various gene networks (Nejad et al., 2019). These small 
non-coding molecules of RNA bind to a target via incomplete attachment which is 
complementary (Salimi et al., 2019) (Nejad et al., 2019). The miRNAs target messenger RNA 
(mRNA) in order to regulate the expression of genes (Salimi et al., 2019), where each mRNA 





gene expression, miRNAs play a vital role during the process of inflammation, angiogenesis 
and apoptosis, which are dysfunctional in preeclampsia (Salimi et al., 2019).  
Placental processes, like the invasion of trophoblast cells, as well as immune activation, are  
regulated by miRNAs (Salimi et al., 2019). During the gestation period, the placenta expresses 
miRNAs. The expression of these miRNAs is altered during the different pregnancy stages 
(Salimi et al., 2019). Modified miRNA levels have also been detected within the placenta of 
preeclamptic individuals (Salimi et al., 2019). Preeclampsia is a multi-gene, polygenic 
disorder of pregnancy (Peixoto et al., 2018). Hence, the pathogenesis of preeclampsia may be 
affected by genetic alterations (Salimi et al., 2019).  
1.3.8 Preeclampsia risk factors  
There are multiple predisposing risk factors which increase the possibility of developing 
preeclampsia (Table 1) (Armaly et al., 2018). Conditions like antiphospholipid syndrome, 
chronic renal disease and previous preeclampsia are some of the risk factors associated with 
preeclampsia (Armaly et al., 2018). Another factor is obesity which results in inflammation, 
insulin resistance and increased risk of developing preeclampsia (Lokki et al., 2018). 
Furthermore, studies have shown that the onset of preeclampsia is higher in women that have 
fathers born from preeclamptic pregnancies (Salimi et al., 2019). 
 
Table 1: Predisposing risk factors associated with preeclampsia development. CI = confidence interval; 







1.3.9 Complications of preeclampsia  
Common maternal complications associated with severe cases of preeclampsia include 
placental abruption, acute kidney injury, pulmonary edema and the HELLP (haemolysis, 
elevated liver enzymes, low platelet count) syndrome (Machado et al., 2012).  The HELLP 
syndrome is also suggested to have similar mechanisms to preeclampsia, such as a decrease of 
pro-angiogenic factors, as well as an elevation of anti-angiogenic factors (Machado et al., 
2012). Restriction of fetal growth, neural damage caused by hypoxia and neonatal death are 
some of the fetal complications associated with severe cases of preeclampsia (Machado et al., 
2012). The management of preeclampsia includes discontinuance of pregnancy (< 24 weeks), 
expectant management (24-32 weeks) or delivery (≥ 32 weeks) (Figure 4) (Machado et al., 









Figure 4: Proposed algorithm for the management of preeclampsia. AKI = acute kidney injury; BP = 
blood pressure; HELLP = haemolysis, elevated liver enzymes and low platelet count; MgSO4 = 







1.4 HIV-associated preeclampsia 
 
Both HIV infection and preeclampsia are common causes of maternal mortality (Moodley et 
al., 2013). During normal pregnancy, an altered immune sensitivity arises, thus permitting 





immune response which is exaggerated (Thakoordeen et al., 2017). This exaggerated immune 
response is presumed to be neutralised by the decreased immune activity and lowered immune 
response associated with HIV infection (Thakoordeen et al., 2017). 
 
The correct use of antiretroviral therapy inhibits replication of HIV, improves the function of 
the immune system and decreases the risk of developing complications associated with AIDS 
(Deeks et al., 2013). It is a standard of care practice in SA to receive highly active 
antiretroviral therapy (HAART) to treat HIV infection during pregnancy (Phoswa et al., 
2018). HAART has the ability to decrease replication of HIV in the mother, along with 
reducing HIV transmission from mother to offspring (Pillay et al., 2019).  
The link between HIV infection, the effect of HAART and the development of preeclampsia is 
conflicting (Pillay et al., 2019). The administration of HAART induces reconstitution of the 
immune system, restoring the maternal immune response, which as a result, makes women 
more susceptible to developing preeclampsia (Moodley et al., 2013). The risk of developing 
preeclampsia is supposedly higher in HIV-infected women compared to women that do not 
have HIV (Phoswa et al., 2018).  Preeclampsia is also purported to be more prevalent in HIV-
infected patients on HAART compared to untreated HIV-infected patients due to 




Selectins are a family of calcium-dependent glycoproteins which bind to a carbohydrate 
ligand and facilitate the movement of leukocytes from blood vessels into tissue (Feng, 2017). 
The selectin family consists of L-selectin, E-selectin and P-selectin (Vestweber, 1999). L-
selectin is expressed by leukocytes and plays an essential role in the rolling of lymphocytes, 
while E-selectin and P-selectin are expressed by activated platelets and endothelial cells, 
respectively (Feng, 2017). The shared structural components of these selectins include a 
lectin-like domain at the NH2-terminus, an epidermal growth factor-like domain (EGF), 
various short consensus repeat domains (CRs), a single transmembrane region and a C-
terminal cytoplasmic domain (Figure 5) (Feng, 2017) (Silva et al., 2018). Soluble E-selectin 
(sE-selectin)  in specific, is a cleavage form of E-selectin that is membrane-bound, hence the 








Figure 5: Structural components of selectin family members. The structural domains include a C-type 
lectin domain, an epidermal growth factor-like domain (EGF), a varying number of short consensus 
repeats, a transmembrane region and a cytoplasmic domain. Adapted from (Silva et al., 2018). 
 
 
1.6 The function of soluble E-selectin 
 
The function of adhesion molecules includes the regulation of leukocyte migration into the 
perivascular tissue as well as the attachment of leukocytes to endothelial cells (Carty et al., 
2012). Interaction between leukocytes and the endothelium is facilitated by sE-selectin during 







Figure 6: Leukocyte recruitment and migration. E-selectin expressed on the endothelial cell surface 
binds to the E-selectin ligand on the surface of leukocytes (Step 1- Tethering/Rolling). Chemokines 
(released by macrophages) bind to chemokine receptors found on the surface of leukocytes, resulting in 
the activation of integrins (Step 2- Integrin Activation). Active integrins bind to integrin ligands on the 
surface of leukocytes which results in adhesion of the leukocyte to the endothelium (Step 3- Firm 
Adhesion). The leukocyte then migrates across the endothelial barrier towards surrounding tissue (Step 
4- Extravasation). EC-endothelial cell. Adapted from (Silva et al., 2018). 
 
The endothelium also regulates the activation and adhesion of neutrophils via cell adhesion 
molecule expression. One of the cell adhesion molecules (CAMs) that facilitate the adhesion 
of neutrophils to the endothelium is sE-selectin (Lyall and Greer, 1996). Neutrophil activation 
in many diseases including preeclampsia is associated with elevated CAM expression (Lyall 
and Greer, 1996). It is therefore plausible that CAMs may play a role in the activation of 
neutrophils which arises during preeclampsia. Since sE-selectin is an adhesion molecule it is 
predictable that its concentration would be higher in preeclamptic women compared to non-
pregnant women (Lyall and Greer, 1996). 
 
Cytokines such as interleukin-1 (IL-1) or TNF-α, as well as lipopolysaccharide, trigger the 
expression of sE-selectin (Vestweber, 1999), resulting in increased levels of this glycoprotein 
possibly due to the activation and damage of endothelial cells (Carty et al., 2012). The anti-
inflammatory cytokine interleukin-10 suppresses pro-inflammatory cytokines like TNF-α 
(Raghupathy, 2013). The expression of sE-selection also can be inhibited by interleukin-4 
      Leukocyte 




while transforming growth factor-β and glucocorticoids have the ability to counteract sE-
selectin expression induced by cytokines (Vestweber, 1999). 
 
1.7 Thrombospondins   
 
The thrombospondin (TSP) family are a group of extracellular glycoproteins which include 
TSP-1, -2, -3, -4 and -5 (Lawler, 2000). These proteins aid in intercellular communication as 
well as communication between cells and the extracellular matrix (Lawler, 2000). They also 
play a role in the remodelling of vasculature, as well as cardiac remodelling (Mirochnik et al., 
2008). Thrombospondin-1 and 2 have similar structural domains (Mirochnik et al., 2008) that 
comprise of an N-terminal domain (THBS-N), an oligomerization domain, a von Willebrand 
Factor type C (VWC) domain, three thrombospondin repeats (TSRs), and a signature domain 
comprising three epidermal growth factor (EGF)-like repeats, a calcium-binding wire and a 
lectin-like C-terminal globe (Figure 7) (Carlson et al., 2008). 
  
 
Figure 7: Modular structures of Thrombospondin (THBS) family members. THBS-1 and -2 comprise 
Group A and form trimers. THBS-3, -4, and -5 comprise Group B and form pentamers. The modules 
are coloured as follows: THBS-N (red), oligomerization coiled-coil (orange), VWC (yellow), TSR1–3 
(shades of green), EGF-like repeats (shades of blue-green, with predicted or known calcium-binding 
repeats coloured in the darkest shade), calcium-binding wire (blue), lectin-like module (purple). The N- 







1.7.1 Thrombospondin-1 and -2   
Thrombospondin-1, which is located in the extracellular space stimulates vascular smooth 
muscle cell migration while also suppressing endothelial cell motility as well as chemotaxis 
(Mirochnik et al., 2008). Thrombospondin-1 promotes apoptosis in T cells and endothelial 
cells (Mirochnik et al., 2008). This glycoprotein also has the ability to interact and bind to 
receptors including CD47, CD36 and certain integrins (Krady et al., 2008).  
 
In addition to TSP-1 and -2 sharing structural similarities, they also have functional homology 
(Mirochnik et al., 2008). One such function is the ability of both TSP-1 and -2 to interact with 
the low-density lipoprotein receptor, which leads to the inhibition of microvascular 
endothelial cell division (Krady et al., 2008). Thrombospondin-1 was first recognised as an 
angiogenesis inhibitor; however, TSP-2 also inhibits angiogenesis (Krady et al., 2008) by 
affecting proliferation and causing endothelial cells to undergo apoptosis (Stenczer et al., 
2011). While TSP-1 and -2 display anti-angiogenic properties which aid in the regulation of 
angiogenesis, studies have suggested that these proteins also regulate tumour angiogenesis 
(Krady et al., 2008). 
 
1.7.2 The function of Thrombospondin-2 
Thrombospondin-2 is secreted mainly by endothelial cells. This glycoprotein plays a 
regulatory role in the extracellular matrix and the process of angiogenesis (Mirochnik et al., 
2008). Angiogenesis facilitates placental development by enhancing circulation and flow of 
blood within the placenta, which contributes to effective placentation (Geldenhuys et al., 
2018).  
However, in preeclampsia, an imbalance of angiogenic and anti-angiogenic placental factors 
exists. More specifically, an increase in anti-angiogenic proteins such as soluble Fms-like 
Tyrosine Kinase 1 (sFlt1) and soluble Endoglin (sEng) is evident with a concomitant 
downregulation of vascular endothelial growth factor (VEGF) and placental growth factor 
(PlGF) (Govender et al., 2015; Ngene et al., 2019).  
The expression of sFlt1 occurs on endothelial, inflammatory and trophoblast cells (Lokki et 
al., 2018). Cells of the placenta also secrete sFlt1 (Geldenhuys et al., 2018). In order to fulfil 
its anti-angiogenic role, the sFlt1protein blocks PlGF and VEGF signalling, therefore 




Although TSP-2 plays a role in angiogenesis regulation, healing of wounds and haemostasis, 
its anti-angiogenic properties affect platelet aggregation, stimulate endothelial cell apoptosis 
and restrict proliferation (Stenczer et al., 2011; Krady et al., 2008). Thrombospondin-2 also 
displays anti-inflammatory properties by stimulating anti-inflammatory regulatory T-cells 
which aid in the suppression of inflammation (Nakao and Morita, 2019). 
 
 
1.8 Aim and objectives of this study 
 
HIV infection and PE have a substantial impact on the high prevalence rate of maternal 
mortality and morbidity in South Africa. There is a dire paucity of data on the effect of sE-
selectin and TSP-2 in the duality of HIV infection and PE hence the aim of this study was to 
determine the role of soluble E-selectin and thrombospondin-2 in the duality of HIV 
associated preeclampsia. 
 
Objectives of the study include: 
 
-To determine the effect of pregnancy type (normotensive versus preeclampsia) on the 
concentration of sE-selectin, irrespective of HIV status. 
 
-To determine the effect of pregnancy type (Normotensive versus preeclampsia) on the 
concentration of thrombospondin-2, irrespective of HIV status. 
 
-To determine the effect of HIV status (HIV positive versus HIV negative) on the 
concentration of sE-selectin, irrespective of pregnancy type. 
 
-To determine the effect of HIV status (HIV positive versus HIV negative) on the 
concentration of thrombospondin-2, irrespective of pregnancy type. 
 
-To compare and contrast the concentration of sE-selectin across the study population.  
 





-To correlate maternal clinical and demographic findings with sE-selectin and 










































Original Article: The role of thrombospondin-2 (TSP-2) in HIV-associated preeclampsia 
Chapter 2 is an original article submitted to European Journal of Obstetrics & Gynecology and 
Reproductive Biology, which is a DOHET accredited international journal. It investigates the 
role of thrombospondin-2 (TSP-2) in HIV-associated preeclampsia. This study revealed a 
significant elevation of TSP-2 in preeclamptic and HIV positive pregnancies. Also, a 
significant upregulation of TSP-2 was found in HIV-associated preeclampsia. 
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Objective: TSP-2 is a glycoprotein that influences cellular activities such as 
proliferation, motility, and apoptosis. Additionally, it is a regulator of the extracellular 
matrix, inflammation and angiogenesis. In preeclampsia, angiogenesis is dysregulated 
due to an imbalance of angiogenic and anti-angiogenic placental factors. In light of the 
high rate of HIV infection in South Africa, this study determined the serum 
concentration of thrombospondin-2 (TSP-2) in HIV-associated preeclampsia. 
Study design: This study utilised retrospectively collected serum samples from 
normotensive pregnant (n = 36) and preeclamptic (n = 36) groups. The latter group was 
subdivided into HIV positive and HIV negative women. TSP-2 levels were measured 
using the Bio-Plex immunoassay technique.  
Results: A statistical difference was noted across the study groups for gestational age, 
systolic blood pressure, diastolic blood pressure and baby weight (p < 0.0001). Based 
on pregnancy type, a significant elevation (p = 0.0429) of TSP-2 was observed in 
preeclamptic (median = 25.35 ng/ml; 95% CI: 34.88-28.47) compared to normotensive 
pregnant (median = 24.80 ng/ml; 95% CI: 27.36-23.83) women. Regardless of 
pregnancy type and based on HIV status, a significant increase of TSP-2 levels (p = 
0.0095) was observed in HIV positive (median = 28.99 ng/ml; 95% CI: 37.41-26.98) 
compared to HIV negative (median = 24.80 ng/ml; 95% CI: 28.88-21.26) women. 
Additionally, based on pregnancy type and HIV status, TSP-2 levels were statistically 




Conclusion: Our findings reveal a significant elevation of TSP-2 levels in preeclamptic 
compared to normotensive pregnancies, regardless of HIV status. This upregulation 
may account for the defective trophoblast cell invasion in preeclampsia. Furthermore, 
based on HIV status, a significant upregulation of TSP-2 levels was noted, and this may 
be attributed to the action of tat protein. TSP-2 may be utilised as a biomarker for the 
early detection of preeclampsia. 
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Maternal mortality in South Africa is high due to HIV and other related infections, 
haemorrhage and hypertension in pregnancy (1). HIV infection affects 13.5%  of the 
total South African population, 20% of whom are in their reproductive age (2). 
Preeclampsia accounts for the majority of deaths emanating from hypertension in 
pregnancy (1). Due to the high prevalence of these medical conditions, research into this 
duality is imperative.  
The systemic endothelial cell activation and dysfunction in preeclampsia, causes 
endothelial cells to secrete thrombospondin-2 (TSP-2) (3, 4). The thrombospondin 
family are a group of calcium-binding glycoproteins which include TSP-1, -2, -3, -4 and 
-5 (5). Each isomer has distinct roles emanating from the regulation of its genetic 
transcription (6). Thrombospondins are a major component of platelets and the 
extracellular matrix (6, 7). TSP 1 and 2 have similar cohesive functions in apoptosis, 
platelet aggregation and inflammation (7). TSP-2 is also involved in the assembly of 
connective tissue components (8). Moreover, TSP-2 is highly expressed in developing 
blood vessels (9). TSP-2 is an inhibitor of angiogenesis which may arise from its TGF-β 
independent activity localised on its properdin type 1 modules (9). Angiogenesis is 
essential for effective placentation during pregnancy (10). However, in preeclampsia, an 
imbalance of angiogenic factors is evident with a decrease in pro-angiogenic factors and 
a concomitant elevation of anti-angiogenic factors (11). In HIV infection angiogenesis 
is dysregulated (12). Therefore, in light of the anti-angiogenic role of TSP-2, this study 
aimed to investigate, the role of TSP-2 in HIV-associated preeclamptic versus 






METHODS AND MATERIALS 
Ethical approval- Institutional ethical permission for this study (BCA338/17) was 
obtained from the Biomedical Research Ethics Committee, University of KwaZulu-
Natal.   
Study population- Post informed consent, the study population consisted of 
normotensive pregnant (n = 36) and preeclamptic (n = 36) participants. Both groups 
were further stratified by HIV status into normotensive HIV negative (n = 14), 
normotensive HIV positive (n = 22) , preeclamptic HIV negative (n = 18) and 
preeclamptic HIV positive (n = 18) pregnant women. Preeclampsia was defined as a 
new-onset high blood pressure (systolic blood pressure ≥140mmHg or diastolic blood 
pressure ≥90mmHg) together with one or more of the following conditions: proteinuria 
(urinary protein ≥300mg per 24 hours), maternal organ dysfunction or uteroplacental 
dysfunction, with such characteristics developing at or after 20 weeks of gestation (13).  
The exclusion criteria for the latter group was polycystic ovarian syndrome, eclampsia, 
chronic hypertension, intrauterine death, abruption placentae, pre-gestational or 
gestational diabetes, chronic diabetes, systemic lupus erythematosus, chronic renal 
disease, sickle cell disease, thyroid disease, antiphospholipid antibody syndrome, 
cardiac disease, pre-existing seizure disorders, active asthma that required medication 
during the gestation period, unknown HIV status as well as patients that were not 
booked into the hospital.  
Sample type- This study utilised retrospectively collected serum samples from women 




Milliplex multiplex method- The concentration of TSP-2 was quantified using the 
MilliPlex Human Angiogenesis Magnetic Bead Panel 2 kit according to the 
manufacturer’s instructions (MILLIPLEX
®
 MAP Human Angiogenesis Panel 2, 
catalogue no: HANG2MAG-12K). Assay buffer (200μl) was added to a 96-well plate. 
Thereafter, 25μl of standards, controls, assay buffer, serum matrix solution, serum 
samples and antibody-immobilized beads were added to the appropriate wells. The plate 
was then incubated with agitation at 2-8℃ overnight. After incubation, 200μl of wash 
buffer was used to wash the plate 3 times; detection antibodies were dispensed into each 
well, followed by incubation with agitation at room temperature for 1 hour. The reporter 
conjugate Streptavidin-Phycoerythrin was added to each well and incubated with 
agitation at room temperature for 30 minutes. Lastly, the plate was washed with wash 





Multiplex Reader (Bio-Rad Laboratories Inc., USA) was used to read the plate and the 
Bio-Plex Manager
™
 analysis software version 4.1 was used to analyse the data.  
Statistical analysis- All statistical analysis was completed using GraphPad Prism 
version 5.00 (GraphPad Software, San Diego, California, USA). The Kolmogorov 
Smirnov normality test was used to determine that the data were non-parametrically 
distributed. A Mann-Whitney U test was to determine significance based on pregnancy 
type (normotensive vs preeclamptic) and HIV status (negative vs positive). One-way 
ANOVA analysis of variance test along with Dunn’s post hoc test (for multiple 
comparisons) was used to determine statistical significance across all study groups. The 
non-parametric data were presented as median and interquartile range. A value of p < 





Patient demographic and clinical characteristics- Table 1 displays the demographical 
data and clinical characteristics of patients across the study groups. Gestational age, 
systolic blood pressure, diastolic blood pressure and baby weight were statistically 
different across the study groups (p < 0.0001). Gestational age was lower in 
preeclamptic women than in normotensive women. The systolic and diastolic blood 
pressures were higher in the preeclamptic group compared to the normotensive group. 
Baby weight was lower in the preeclamptic group compared to the normotensive group. 
Maternal age, maternal weight, parity and gravidity did not exhibit any statistical 
difference. Maternal age varied from 18 to 43 years. Maternal weight was higher in the 
preeclamptic HIV negative group compared to the rest of the study groups. The 
preeclamptic HIV positive group consisted of a twin pregnancy.  
Serum concentrations of TSP-2 
Pregnancy type- As shown in Figure 1A, regardless of HIV status and based on 
pregnancy type (normotensive vs. preeclamptic) a significant difference was observed in 
the levels of TSP-2 (p = 0.0429). An upregulation trend in the concentration of TSP-2 
was noted in the preeclamptic (median = 25.35 ng/ml; 95% CI: 34.88-28.47) compared 
to the normotensive group (median = 24.80 ng/ml; 95% CI: 27.36-23.83). 
HIV status- Regardless of pregnancy type, a significant difference was observed in TSP-
2 (p = 0.0095) levels based on HIV status (negative vs. positive). A significant increase 
in the concentration of TSP-2 was noted in the HIV positive group (median = 28.99 
ng/ml; 95% CI: 37.41-26.98) compared to the HIV negative group (median = 24.80 




Across all groups- Based on pregnancy type and HIV status, TSP-2 levels were 
statistically significant across all groups (p = 0.0229). The concentration of TSP-2 was 
higher in the preeclamptic HIV positive group (median = 37.49 ng/ml; 95% CI: 47.19-
28.83) compared to the preeclamptic HIV negative group (median = 25.34 ng/ml; 95% 
CI: 31.72-18.96) (Table 2 and Figure 1C). The concentration of TSP-2 was also 
elevated in the normotensive HIV positive group (median = 26.38 ng/ml; 95% CI: 
30.88-21.89) compared to the normotensive HIV negative group (median = 24.80 
ng/ml; 95% CI: 29.54-20.06). Additionally, the concentration of TSP-2 was statistically 
significant between the normotensive HIV negative group and the preeclamptic HIV 
positive group (p = 0.0290). The concentration of TSP-2 was also statistically 
significant between the preeclamptic HIV negative group and the preeclamptic HIV 











































































































































































































































































































Figure 1. Serum concentrations of TSP-2 (ng/ml): (A) Normotensive (N) vs 
Preeclamptic (PE) groups. *Serum concentrations of TSP-2 are statistically different 
between the normotensive and preeclamptic group, p = 0.0429.  (B) HIV-negative 
(HIV-) vs HIV-positive (HIV+) groups. **Serum concentrations of TSP-2 are 
statistically different between the HIV-negative and HIV-positive group, p = 0.0095. 
(C) Normotensive HIV-negative (N-); Normotensive HIV-positive (N+); Preeclamptic 
HIV-negative (PE-) and Preeclamptic HIV-positive (PE+) groups. *Serum 
concentrations of TSP-2 are statistically different between the normotensive HIV-
negative group and the preeclamptic HIV-positive group, p = 0.0290. **Serum 
concentrations of TSP-2 are statistically different between the preeclamptic HIV-







To the best of our knowledge, this is the first study to report upregulation of serum 
concentration of TSP-2 in an HIV positive preeclamptic cohort. We report a significant 
difference in serum TSP-2 concentration based on pregnancy type, irrespective of HIV 
status. TSP-2 is a calcium-binding glycoprotein that is involved in cellular activities 
such as apoptosis, angiogenesis and aids in communication between cells and the 
extracellular matrix, affecting cellular functions such as proliferation and invasion (4, 
14, 15). Additionally, TSP-2 also plays a role in the remodelling of the vasculature (3, 
5, 16). It is therefore plausible that TSP-2 may account for the dysfunctional invasion of 
trophoblast cells in preeclampsia. Preeclampsia is associated with defective trophoblast 
cell invasion that culminates in inhibition of myometrial spiral artery remodelling (17). 
Since TSP-2 regulates the bioavailability of proteases, it would regulate cell migration 
as well as the physiological transformation of the spiral artery (8, 18).  
Notably, integrins have a vital role in regulating cell behaviour, proliferation and 
migration (19). Specifically, α4β1 integrins are receptors for TSP-2 (20) therefore, the 
dysregulation of TSP-2 noted in our study may emanate from an aberrant integrin 




Moreover, microRNAs play an essential role in regulating migration and invasion of 
trophoblasts. Recently, the overexpression of miR-221-3p was shown to stimulate the 
growth of trophoblasts, migration as well as invasion. In contrast, miR-221-3p knockout 
has an opposing effect (22). This study reported that the mRNA expression of TSP-2 
was elevated in preeclampsia and was negatively correlated with miR-221-3p. These 
findings corroborate our findings of an up-regulation of serum TSP-2 in preeclampsia 
and highlight the role of TSP-2 in trophoblast cell migration.  
The expression of TSP-2 is modulated by hypoxia (3). Verma et al. (2018) reported 
elevated expression of HIF-1α in preeclampsia compared to normotensive pregnancies 
(23). Therefore, the ischaemic microenvironment of preeclampsia could contribute to 
the upregulation of TSP-2 in preeclampsia, as observed in our study.  
Preeclampsia is characterised by a dysfunctional endothelium and endotheliosis (24). It 
is also widely accepted that in preeclampsia the anti-angiogenic proteins, sFlt1 and sEng 
are upregulated with a concurrent decline in VEGF and PlGF (25, 26).  
A study conducted by Govender et al. (2013) reported that the levels of anti-angiogenic 
soluble Fms-like Tyrosine Kinase 1 (sFlt1) are higher in HIV negative pregnancies 
(preeclamptic and normotensive) than in HIV positive pregnancies and suggests 
neutralisation of the exaggerated immune response in preeclampsia (27). sFlt1 works by 
blocking pro-angiogenic proteins such as placental growth factor and vascular 




TSP-2 has been demonstrated to be anti-angiogenic, pro-apoptotic and 
immunomodulatory (3). In our study, the elevated serum TSP-2 levels may be due to 
the systemic endothelial damage emanating from its angiogenic inhibitory role. The 
anti-angiogenic function of TSP-2 is reliant on its interaction with the CD36 receptor 
(29). Structurally, TSP-2 contains type 1 repeats which bind to CD36 on the membrane 
of endothelial cells; this binding inhibits angiogenesis by inducing endothelial cell 
apoptosis (30, 31).  
Subsequent to the damage of tissue, thrombospondins regulate remodelling and 
inflammation (32). The expression of TSP-2 is elevated during the remodelling of tissue 
which is associated with inflammation (33). Park et al. (2004) showed that during an 
autoimmune disease such as rheumatoid arthritis, TSP-2, a constituent of the synovial 
microenvironment, regulates tissue inflammation (34). TSP-2 causes suppression of 
inflammation by activating regulatory anti-inflammatory T-cells (35). The elevated 
TSP-2 observed in our study reflects the hyper-inflammatory environment of 
preeclampsia.  
In this study, TSP-2 was significantly different by HIV status with an increasing level in 
HIV positive women. The antiviral property of TSP-2 observed in our study is 
corroborated by a number of other studies (36, 37). The mechanism of action involves 
the binding of tat protein (the transactivator of HIV-1) to TSP-2 (37). Tat is a potent 
angiogenic factor due to its similar arginine and lysine-rich sequence to VEGF (38). 
Therefore, in our study, it is plausible that the binding of the tat protein to TSP-2 




Additionally, the upregulation of TSP-2 observed in the HIV positive group in our study 
may be attributed to the binding affinity of TSP-2 to gp120 of HIV-1 via CD36 (36). 
More specifically the conserved regions flanking the V3 loop of gp120 provide the 
antiviral property for direct HIV-1 inhibitory activity of TSP.  
It is important to note that the HIV positive group in this study received dual 
antiretroviral therapy (HAART + Nevirapine). It has been previously demonstrated that 
HAART may influence the HIV-1 matrix protein p17 to induce the secretion of TSP-1 
(39). 
Our results demonstrate significant upregulation of TSP-2 in HIV-associated 
preeclampsia. The effect of TSP-2 in the hypoxic, inflammatory microenvironment of 
preeclampsia combined with the anti-angiogenic effect of TSP-2 reduces its 
bioavailability for VEGF binding. 
CONCLUSION  
In conclusion, this study demonstrates significant upregulation of TSP-2 in preeclamptic 
vs normotensive pregnancies as well as when stratified by HIV status. Additionally, a 
significant elevation of TSP-2 in HIV-associated preeclampsia was also noted. TSP-2 
has predictor test value in the early diagnosis of preeclampsia due to its role in the 
remodelling of vasculature, angiogenesis regulation, apoptosis and inflammation. 
Finally, further large scale studies are required to confirm its biomarker value for 
preeclampsia development. 
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Original Article: The role of soluble E-selectin (sE-selectin) in HIV-associated 
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groups. 
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Purpose: To determine the serum concentration of soluble E-selectin (sE-selectin) in 
HIV associated preeclampsia. 
Methods: The study population (n = 72) consisted of normotensive pregnant (n = 36) 
and preeclamptic (n = 36) women stratified by HIV status (negative vs. positive). Serum 
concentrations of sE-selectin were quantified using the Bio-Plex immunoassay.  
Results: Based on pregnancy type and HIV status, serum sE-selectin levels were 
elevated in the preeclamptic HIV-negative group compared to the normotensive HIV-
negative group (p = 0.0070). Gestational age, systolic blood pressure, diastolic blood 
pressure and baby weight were statistically different across the study groups (p < 
0.0001).  
Conclusion: This study demonstrates an elevation of sE-selectin in preeclamptic HIV-
negative compared to the normotensive HIV-negative group. However, based on HIV 
status, there was no significant difference observed in preeclamptic HIV-positive and 
normotensive HIV-positive groups. Therefore, sE-selectin may be used as a biomarker 
or an early identifier of preeclampsia.  
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The Human Immunodeficiency Virus (HIV) infection is a global health concern, with 
sub-Saharan Africa being the region most affected by the epidemic [1]. In South Africa 
(SA), the prevalence of HIV infection is exceedingly high, with 7.5 million people 
being infected [2]. The epicentre of this epidemic is the province of KwaZulu-Natal 
where the prevalence of HIV infection during pregnancy is approximately 41.1% [3]. In 
2018, one-fifth of women in SA, in the reproductive ages between  15 to 49 years were 
HIV positive; hence, this presents a sombre quandary for health care professionals [2]. 
Furthermore, both HIV infection and preeclampsia are common causes of maternal 
mortality [4]. 
Preeclampsia (PE) is a major obstetric concern affecting approximately 2-8% of 
pregnancies globally, while in SA maternal deaths caused by hypertensive disorders of 
pregnancy is 14.8% [5, 6]. In order for PE to be effectively treated, both the fetus and 
placenta require urgent delivery [7]. The placenta is crucial for the growth and 
development of the fetus as it continually develops and adapts to meet increasing fetal 
metabolic requirements [8, 9]. Maternal structural modifications also occur during 
healthy pregnancies where cytotrophoblasts invade the decidua and myometrium of the 
uterus and remodel the spiral arteries [10]. The above  is necessary for efficient supply 
of blood (containing oxygen and nutrients) to the fetus [11]. In PE, however, 
cytotrophoblast invasion is limited resulting in the incomplete physiological conversion 
of the myometrial spiral arteries [11, 12]. The maladaptation of the uterine spiral 
arterioles leads to placental hypoxia/stress from reduced blood flow and physiological 
assessment indicates endothelial dysfunction, vasospasm, a systemic inflammatory 




The circulating adhesion molecule soluble E-selectin (sE-selectin), expressed on 
endothelial cells, is activated by inflammation or stress [14]. This adhesion molecule 
plays a vital role in transporting immune cells to areas of inflammation and facilitates 
interaction between circulating leukocytes and the endothelium. Ligands found on the 
surface of endothelial cells bind to sE-selectin resulting in leukocytes being recruited to 
the endothelium [14-16]. Since endotheliosis is a pathognomonic lesion of PE, levels of 
sE-selectin are altered in this disorder [16]. The activation and damage of endothelial 
cells contribute to the increasing sE-selectin levels [16]. The release of cytokines like 
tumour necrosis factor-alpha (TNF-α) upregulates the expression of sE-selectin [15].  
Cytokines can also be categorised as T helper 1 (Th1) cytokines and T helper 2 (Th2) 
cytokines, where Th1 cytokines have the ability to induce inflammatory and cytotoxic 
reactions while Th2 cytokines are associated with humoral immunity [17]. These 
cytokines are involved in HIV infection pathogenesis where HIV positive individuals 
display a shift from Th1 immune response to Th2 immune response [18].  
Activation of the immune system and release of inflammatory cytokines are associated 
with HIV infection [19]. The regulatory HIV protein Tat activates pro-inflammatory 
cytokine production and induces an elevation in mediators of inflammation such as sE-
selectin [20]. HIV infection influences soluble adhesion molecule expression and in 
serum, leads to abnormal adhesion molecule levels [21]. 
In view of the altered sE-selectin expression in PE, there is a possibility that this protein 
may have value as a predictive biomarker of PE development. The identification of 
predictive biomarkers is a challenge as the development of PE commences in the first 
trimester of pregnancy, prior to the appearance of clinical symptoms [12]. Hence, 
further research is required in order to identify potential biomarkers that may be utilised 
as early indicators of PE development. Therefore, the aim of this study was to compare, 
for the first time, the role of sE-selectin in preeclamptic and normotensive pregnancies 
compromised by HIV infection.  
 





Institutional ethical approval (BCA338/17) was obtained. The study utilised serum 
samples retrospectively collected from women who attended a large regional hospital in 
Durban, South Africa. The study population (n = 72) consisted of normotensive 
pregnant (n = 36) and preeclamptic (n = 36) women. Both these groups were further 
stratified by HIV status. Patients unable to provide informed consent were excluded. 
Women with a history of other co-existing medical disorders and infections other than 
PE and HIV were excluded from the study. Normotensive primigravid and multigravid 
women constituted the control group. PE is a pregnancy-specific condition characterised 
by new-onset high blood pressure (systolic blood pressure ≥140mmHg or diastolic 
blood pressure ≥90mmHg) together with one or more of the following conditions: 
without proteinuria or with proteinuria (urinary protein ≥300 mg per 24 hours), maternal 
organ dysfunction, liver and renal injury or intra-uterine growth restriction, with such 
characteristics developing at or after 20 weeks of gestation [22].   
MilliPlex multiplex method  
The MilliPlex Human Angiogenesis Magnetic Bead Panel 2 kit was used to quantify the 
concentration of sE-selectin according to the manufacturer’s instructions 
(MILLIPLEX
®
 MAP Human Angiogenesis Panel 2, catalogue no: HANG2MAG-12K). 
The bead-based flow cytometric mechanism of this immunoassay enabled multiplex 
analyses. The assay included the incubation of the antigen sample, i.e., sE-selectin, with 
the capture of antibody-coupled beads. Subsequent to washing, which ensured the 
removal of unbound substances, an additional incubation with biotinylated detection 
antibodies was carried out. The plate was thereafter washed to remove any unbound 
biotinylated detection antibodies and the beads were incubated with streptavidin-
phycoerythrin (SA-PE) which is a reporter conjugate. Following a third and final wash 
to clear the plate of excess SA-PE, the beads flowed through an array reader which 
determined the fluorescence emitted from bound SA-PE. The Bio-Plex
®
 MAGPIX™ 
Multiplex Reader (Bio-Rad Laboratories Inc., USA) was used to read the samples and 






GraphPad Prism version 5.00 (GraphPad Software, San Diego, California, USA) was 
used for all statistical analysis. The data was non-parametrically distributed. Descriptive 
statistics were used to summarise the data and non-parametric data was presented as 
median and interquartile range. A Mann-Whitney U test was used to determine 
statistical significance based on pregnancy type (normotensive vs. preeclamptic) and 
HIV status (negative vs. positive). One-way ANOVA, i.e., a Kruskal-Wallis test as well 
as the Dunn’s post hoc test (for multiple comparisons) were performed in order to 
determine statistical significance among all study groups. A value of p < 0.05 was 




Table 1 displays patient demographics across all study groups. Gestational age, systolic 
and diastolic blood pressure, as well as baby weight, were statistically significant across 
the study groups (p < 0.0001). A lower gestational age was observed in the PE group 
compared to the normotensive group (p = < 0.0001). A lower baby weight was also 
observed in the preeclamptic group compared to the normotensive group (p = < 0.0001). 
There was no statistical significance observed in maternal age, maternal weight, parity 
and gravidity (table 1).   
Serum concentrations of sE-selectin  
Pregnancy type 
Based on pregnancy type, normotensive (mean = 110.6 ng/ml; 95% CI: 125.5-95.69) vs. 
preeclamptic (mean = 123.6 ng/ml; 95% CI: 140.4-106.7), there were no significant 
difference in the levels of sE-selectin (p = 0.0708) irrespective of HIV status as shown 
in Table 2 and Fig. 1a. However, an upward trend in sE-selectin level, albeit non-





As shown in Table 2 and Fig. 1b, based on HIV status, negative (mean = 114.7 ng/ml; 
95% CI: 129.8-99.65) vs. positive (mean = 119.4 ng/ml; 95% CI: 136.3-102.5), there 
was no significant difference in sE-selectin levels (p = 0.7227) regardless of pregnancy 
type. However, an increase in the concentration of sE-selectin was noted in the HIV-
positive group compared to the HIV-negative group. 
 
 
Pregnancy type and HIV status 
Based on pregnancy type and HIV status, the concentration of sE-selectin was 
statistically significant between the normotensive HIV-negative and preeclamptic HIV-
negative group (p = 0.0070
**
) (Table 2 and Fig. 2a). Furthermore, as displayed in Table 
2 and Fig. 2b-e, no significant difference was observed in normotensive HIV-positive 
group and the preeclamptic HIV-positive group (p = 0.5495), the normotensive HIV-
negative and normotensive HIV-positive group (p = 0.0557), the preeclamptic HIV-
negative and preeclamptic HIV-positive group (p = 0.1835) as well as normotensive 






Table 1 Patient demographics in normotensive HIV negative; normotensive HIV 























































































































































































































N = Normotensive, PE = Preeclampsia, HIV = Human Immunodeficiency Virus, - = HIV negative, + = 
HIV positive 























































































Fig. 1 (a) Serum concentrations of sE-selectin (ng/ml): Normotensive (N) and Preeclampsia (PE) groups. 








































































Fig. 2 (a) Serum concentrations of sE-selectin (ng/ml): Preeclamptic HIV-negative (PE-) and 
Normotensive HIV-negative (N-) groups. Serum levels of sE-selectin were significantly elevated in PE- 
groups compared to N- groups (p=0.0070
**
). (b) Serum concentrations of sE-selectin (ng/ml): 








































































Fig. 2 (c) Serum concentrations of sE-selectin (ng/ml): Normotensive HIV-negative (N-) and 
Normotensive HIV-positive (N+) groups. (d) Serum concentrations of sE-selectin (ng/ml): Preeclamptic 







































Fig. 2 (e) Serum concentrations of sE-selectin (ng/ml): Preeclamptic HIV-positive (PE+) and 













Based purely on pregnancy type, this study found no significant differences between the 
normotensive group (HIV positive and HIV negatives combined) and preeclamptic 
(HIV positive and negative combined) group. These findings are similar to others who 
reported no significant difference of sE-selectin in normotensive compared to PE 
pregnancies [23-25].  No significant difference was noted in normotensive positive 
pregnancies compared to PE positives; also, no statistical difference was found between 
normotensive negatives and PE positives.  
The non-significance noted in the current study could be due to antiretroviral therapy 
given to HIV positive pregnant women. Kristofferson et al., (2009), investigated the 
effect of antiretroviral therapy in non-pregnant HIV positive patients and reported a 
decrease in levels of endothelial dysfunction markers in HIV positive patients [26]. 
Another interesting factor that comes into play is that sE-selectin has been reported to 
entrap itself on ligands of circulating leukocytes in order to prevent them from 
relocating to areas of inflammation, in this way, exaggerated inflammation is prevented 
[27]. This may also be the reason why this study found no significance in normotensive 
positive vs PE positive and normotensive negative vs PE positive groups. 
Interestingly, in this study, a significant increase in levels of sE-selectin was found in 
preeclamptic HIV negative compared to normotensive HIV negative groups 
(p=0.0070
**
). Carty et al., (2012) studied levels of sE-selectin in pregnancies 
complicated with PE alone and reported elevated levels of sE-selectin in early 
pregnancies that later developed into PE. The pathophysiology of PE involves poor 
placentation, endothelial dysfunction, inflammation and oxidative stress [16]. Soluble 
E-selectin is a cell adhesion molecule found on endothelial cells [16]. The main function 
of sE-selectin is to control leukocyte cohesion on endothelial cells and the migration of 
white blood cells to perivascular tissue during inflammation [14]. Therefore, 
upregulation of sE-selectin is an indication of endothelial dysfunction, which is one of 




Regardless of pregnancy type, but based purely on HIV status, an upward trend was 
noted in normotensive positive compared to normotensive negative pregnancies albeit 
non-significantly. sE-selectin levels between PE negatives and PE positives showed no 
significant difference; however the PE positive group showed an upward trend of sE-
selectin compared to PE negatives. Levels of sE-selectin showed no significant 
difference between the HIV positive group and the HIV negative group, with an upward 
trend observed in the HIV positive group.   
Our results agree with findings of Hoffman et al., (2018) who reported no significant 
difference in sE-selectin levels in HIV positive compared to HIV negative non-pregnant 
patients [14]. Hoffman et al., (2018) observed levels of sE-selectin in chronic HIV 
positive patients who were on treatment and discovered no correlation of the adhesion 
molecule with inflammation [14]. In addition, Rönsholt et al. (2013) reported a decrease 
in sE-selectin in patients on HIV treatment compared to untreated patients [28]. More 
interestingly, Graham et al., (2013) described levels of sE-selectin to be elevated in HIV 
positive acute patients compared to HIV positive chronic patients which may indicate 
that the admission of HAART may decrease levels of inflammation in HIV positive 
patients who have been on chronic HIV treatment [29]. In the current study, HIV 
positive patients showed an upward trend of sE-selectin, probably due to immune 
activation during infection. According to Rönsholt et al., (2013), levels of sE selectin 
are altered due to HIV treatment but are not regulated to normal levels noted in HIV 




As far as we are aware, this is the first study to report sE-selectin levels in preeclamptic 
patients with HIV infection. Furthermore, it is standard practice for pregnant individuals 
to be tested for HIV and to be treated accordingly. Our results showed no significant 
difference in levels of sE-selectin in preeclamptic HIV positive patients compared to 
preeclamptic HIV negative patients. However, an upward trend was noted in 
preeclamptic HIV positive patients. This may be due to inflammation triggered by 
cytokines such as IL-1 and the tumour necrosis factor-alpha (TNF-α). Tumour necrosis 
factor-alpha activates sE-selectin [15]. Furthermore, Calza et al., (2009) reported a 
correlation between sE-selectin, viral load and CD4
+ 
in HIV non-pregnant positive 
patients [30]. In contrast, Rönsholt et al., (2013) found no correlation between sE-
selectin, viral load and CD4
+
in non-pregnant HIV positive patients.   
The  HIV protein Tat, is a protein that elevates the release of pro-inflammatory 
cytokines and upregulates the expression of sE-selectin by functioning as a cytokine 
during endothelial cell activation [31]. The Tat protein also stimulates the upregulation 
of the adhesion molecule ICAM-1 on endothelial cells, while also upregulating 
mediators of inflammation such as VCAM-1 to inhibit cell migration [31, 32], hence the 
upward trend noted in preeclamptic HIV positive patients in this study. 
Strengths and Limitations 
This study is the first to report on levels of sE-selectin in individuals with both HIV and 
PE. However, larger sample size is required to confirm our findings. Also important to 
note, the HIV patients were not grouped according to their duration and type of 
treatment.  
Conclusion  
This study demonstrates upregulation of sE-selectin in HIV negative preeclamptic 
compared to normotensive HIV negative pregnancies. Soluble E-selectin could possibly 
be used diagnostically, as an early indicator of PE development due to its role in 
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4.1 SYNTHESIS  
 
HIV infection and preeclampsia are common causes of maternal mortality in SA (Saving-
Mothers-Report, 2017). Preeclampsia (PE) only occurs during pregnancy with characteristic 
features that include impaired placentation, systemic inflammation, as well as endothelial 
dysfunction (Rana et al., 2019). The circulating adhesion molecule sE-selectin is a marker of 
endothelial dysfunction (Hoffman et al., 2018). The activation and damage of endothelial cells 
lead to increased levels of this adhesion molecule (Carty et al., 2012). In PE, endothelial cell 
activation and dysfunction results in endothelial cells secreting the glycoprotein TSP-2; this 
indicates a possible association between TSP-2 and PE (Stenczer et al., 2011). The 




manifestation of clinical symptoms (Gathiram and Moodley, 2016). This makes it difficult to 
identify predictor tools that can be utilised in the early diagnosis of PE. Taking into 
consideration the altered levels of sE-selectin and TSP-2 in PE, these analytes may have value 
as early indicators of PE. Therefore, the aim of this study was to investigate the role of sE-
selectin and TSP-2 in HIV-associated PE. 
Based solely on pregnancy type, this study reports no significant difference of sE-selectin 
between normotensive (HIV positive and HIV negative combined) and preeclamptic (HIV 
positive and HIV negative combined) pregnancies. sE-selectin is a marker of endothelial 
dysfunction that is elevated in conditions associated with inflammation (Raffray et al., 2017; 
Hoffman et al., 2018).  
This study demonstrates no significant difference of sE-selectin expression between 
normotensive HIV-positive compared to the preeclamptic HIV-positive groups. In addition, 
the normotensive HIV-negative and preeclamptic HIV-positive groups also did not differ 
significantly. The administration of antiretroviral therapy to pregnant HIV-positive women 
may account for the non-significance reported in this study. While the HIV regulatory protein 
Tat stimulates endothelial dysfunction by binding to integrin receptors, HIV-positive patients 
receiving antiretroviral therapy have been reported to exhibit decreased levels of endothelial 
dysfunction markers (Kristoffersen et al., 2009;Anand et al., 2018). Interestingly, sE-selectin 
can remain attached to ligands present on the surface of circulating leukocytes thereby 
preventing these cells from migrating to inflammatory sites. This ability of sE-selectin 
prevents destructive inflammation during exaggerated leukocyte release and could explain the 
non-significance found in this study between the normotensive HIV-positive and preeclamptic 
HIV-positive groups as well as between the normotensive HIV-negative and preeclamptic 
HIV-positive groups (Raffray et al., 2017). 
A significant elevation of sE-selectin was also observed between the preeclamptic HIV-
negative group and the normotensive HIV-negative group (p=0.0070
**
). The concentration of 
circulating adhesion molecules are elevated in PE (Lylla et al., 1999). Increased levels of sE-
selectin have been reported in early pregnancies which were later complicated with PE (Carty 
et al., 2012). Reduced placentation, placental ischaemia with resultant increase in oxidative 
stress, dysfunction of the endothelium and inflammation contribute to the pathophysiology of 
PE (Geldenhuys et al., 2018). Soluble E-selectin is synthesised and transported to the 
endothelial cell surface where it facilitates the adhesion of leukocytes to endothelial cells 
(Kim et al., 2004;Feng, 2017). During inflammation, sE-selectin regulates the movement of 




selectin indicates dysfunction of the endothelium, which is involved in the pathophysiology of 
PE. 
Irrespective of pregnancy type and based solely on HIV status, this study reports no 
significant difference between normotensive HIV-positive and normotensive HIV-negative 
groups, however the normotensive HIV-positive group exhibited an upwards trend of sE-
selectin compared to the normotensive HIV-negative group. Although levels of sE-selectin 
were non-significant between the preeclamptic HIV-negative and preeclamptic HIV-positive 
groups, an upwards trend of sE-selectin was observed in the preeclamptic HIV-positive 
compared to the preeclamptic HIV-negative group. No significant difference was observed in 
sE-selectin levels between the HIV-positive and HIV-negative groups, however the HIV-
positive group showed an upwards trend of sE-selectin compared to the HIV-negative group. 
Hoffman et al., (2018) reported that levels of sE-selectin did not differ significantly in HIV 
positive compared to HIV negative non-pregnant patients which is in agreement with the 
results reported in this study (Hoffman et al., 2018). Furthermore, decreased sE-selectin levels 
have been reported in HIV positive patients receiving treatment compared to patients not 
receiving HIV treatment (Rönsholt et al., 2013). It is also interesting to note that sE-selectin 
levels are reported to be elevated in patients with acute HIV compared to patients with chronic 
HIV (Graham et al., 2013). This could be indicative of HAART admission possibly lowering 
inflammation levels of patients that are on chronic HIV treatment. The immune activation that 
occurs during HIV infection may account for the upwards trend of sE-selectin noted in the 
HIV-positive group of this study. In addition, HIV treatment reportedly alters sE-selectin 
levels but does not regulate it to the normal levels observed in patients that are HIV-negative 
(Rönsholt et al., 2013). 
To the best of our knowledge, this is the first study to report dysregulated levels of sE-selectin 
in preeclamptic patients compromised by HIV infection. Notably, during pregnancy, testing 
for HIV and receiving appropriate treatment regimens is standard practice. In this study, levels 
of sE-selectin showed no significant difference between the preeclamptic HIV-positive group 
and the preeclamptic HIV-negative group, with an upwards trend observed in the preeclamptic 
HIV-positive group. This could be explained by cytokines such as IL-1 and TNF-α eliciting an 
inflammatory response. Tumour necrosis factor-alpha is also responsible for the activation of 
sE-selectin. 
Furthermore, the upwards trend of sE-selectin observed in the preeclamptic HIV-positive 




during the activation of endothelial cells thereby elevating the release of pro-inflammatory 
cytokines and upregulating sE-selectin expression (Jiang et al., 2018). This HIV protein 
induces elevation of the ICAM-1 adhesion molecule on endothelial cells and also upregulates 
VCAM-1 which is a mediator of inflammation that inhibits cell migration (Jiang et al., 
2018;Padayachee et al., 2019).  
As far as we know, this is the first study to report that TSP-2 is upregulated in preeclamptic 
patients with HIV infection. Regardless of HIV status and based on pregnancy type, this study 
reports a significant difference in the serum concentration of TSP-2. TSP-2 is an extracellular 
glycoprotein that affects the proliferation as well as invasion of cells by aiding in 
communication between cells and the extracellular matrix. TSP-2 is also involved in the 
remodelling of vasculature and could possibly explain the defective trophoblast cell invasion 
of PE (Lawler, 2000;Mirochnik et al., 2008;Stenczer et al., 2011). Since the bioavailability of 
proteases is regulated by TSP-2, cell migration together with physiological conversion of 
spiral arteries would also be regulated by TSP-2 (Pellerin et al., 1994;Bornstein et al., 2000). 
Additionally, microRNAs are involved in the regulation of trophoblast migration and 
invasion. The growth of trophoblasts, migration as well as invasion is reported to be 
stimulated by overexpression of miR-221-3p, while the knockout of this microRNA is shown 
to have the opposite effect (Yang et al., 2019). Moreover, Yang et al., (2019) discovered an 
elevation of TSP-2 microRNA expression in PE which was also negatively correlated with 
miR-221-3p (Yang et al., 2019). The findings of Yang et al., (2019) corroborate the 
upregulation of TSP-2 in PE observed in this study. 
TSP-2 expression is regulated by hypoxia (Stenczer et al., 2011). The expression of HIF-1α is 
reported to be elevated in preeclamptic pregnancies (Verma et al., 2018). Hence, the TSP-2 
upregulation in preeclamptic pregnancies noted in this study may be due to the ischaemic 
microenvironment associated with PE. 
Dysfunction of the endothelium and endotheliosis are characteristic features of PE (Sani et al., 
2019). In PE, there is an elevation of anti-angiogenic proteins such as sFlt1 and sEng which is 
accompanied by a concomitant downregulation of VEGF and PlGF (Govender et al., 
2015;Ngene et al., 2019). Levels of sFlt1 are reported to be higher in HIV-negative 
(preeclamptic and normotensive) compared to HIV-positive pregnancies, therefore suggesting 
that the exaggerated immune response in PE is neutralised (Govender et al., 2013). Soluble 
Fms-like Tyrosine Kinase 1 (sFlt1) dysregulates angiogenesis by blocking the function of pro-




The systemic endothelial damage which arises from the angiogenic inhibitory action of TSP-2 
may account for the upregulation of TSP-2 reported in this study.  The angiogenic nature of 
TSP-2 results in systemic endothelial damage. Interaction between TSP-2 and the CD36 
receptor is responsible for the anti-angiogenic properties displayed by TSP-2 (Silverstein and 
Febbraio, 2009). The binding of TSP-2 to CD36 induces endothelial cell apoptosis and thus 
inhibits angiogenesis (Koch et al., 2011;Fei et al., 2017). 
TSP-2 plays a role in assembling constituents of connective tissue and is upregulated during 
the remodelling of tissue (Bornstein et al., 2000;Bornstein et al., 2004). TSP-2 is reported to 
regulate tissue inflammation in rheumatoid arthritis and also has the ability to activate 
regulatory anti-inflammatory T-cells thereby acting as a suppressor of inflammation (Park et 
al., 2004;Papageorgiou et al., 2012). The elevation of serum TSP-2 noted in this study is 
indicative of the exaggerated inflammatory state seen in PE. 
Based on HIV status, this study reports a significant upregulation of TSP-2 in HIV-positive 
women. TSP-2 binds to the HIV protein Tat (Rusnati et al., 2000). This protein is similar to 
VEGF in sequence which makes it a powerful angiogenic factor (Zhou et al., 2013). Hence, in 
this study it is possible that an antagonistic angiogenic activity is stimulated in HIV infection 
when TSP-2 binds to the Tat protein. 
In addition, the inclination of TSP-2 to bind to the HIV protein gp120 via CD36 could explain 
the elevated levels of TSP-2 noted in the HIV-positive group of this study (Crombie, 2000). 
Notably, in this study, all HIV-positive women received dual antiretroviral therapy (HAART 
+ Nevirapine). HAART also has been reported to possibly stimulate TSP-1 secretion by 
influencing p17 which is a matrix protein of HIV (Caccuri et al., 2014). 
This study also reports a significant elevation of TSP-2 in HIV-associated PE. The 
bioavailability of TSP-2 for VEGF binding is reduced due to the anti-angiogenic properties 
displayed by TSP-2 together with its role in the hyper inflammatory, hypoxic 




To the best of our knowledge, this is the first study to report on the serum concentrations of 




significant upregulation of sE-selectin was observed in preeclamptic HIV-negative compared 
to normotensive HIV-negative pregnancies. However, based on HIV status, there was no 
significant difference of sE-selectin expression observed between the preeclamptic HIV-
positive and normotensive HIV-positive groups. Furthermore, a significant elevation of TSP-2 
was demonstrated in preeclamptic compared to normotensive pregnancies, irrespective of HIV 
status. Based on HIV status, a significant upregulation of TSP-2 was observed in HIV-positive 
women and in HIV-associated PE. This study therefore reflects the biomarker value of sE-
selectin and TSP-2, as early indicators of PE development. 
 
4.3 FUTURE RESEARCH 
 
In light of the role that sE-selectin plays during dysfunction of the endothelium, this adhesion 
molecule could possibly be used as an early indicator of PE. The role of TSP-2 in vasculature 
remodelling, inflammation and as a regulator of angiogenesis makes it suitable to be used 
diagnostically for the early detection of PE. Lastly, further large scale studies to confirm the 
biomarker value of sE-selectin and TSP-2 in PE is crucial as this will aid in developing 
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